Effect of Danshen Injection in the Treatment of Decompensated Chronic Pulmonary Heart Disease and the Impact on Prethrombotic State Markers and Cardiac Function/FAN Lizhen， XIONG Jiangqin， XIONG Zhenni. //Medical Innovation of China，2025，22（20）： 069-073

[Abstract]Objective：To analyze the therapeutic efectof Danshen Injection on patients with decompensated chronic pulmonary heart disease （CPHD）and its influence on prethrombotic state markers and cardiac function. Method：A totalof 8O patients with decompensated CPHD who visited Jiangxi Chest Hospital from May 2023 to July 2024 were selected and divided into control group and treatment group according to the random number table method，with 4O cases ineach group.The control group was given conventional treatments suchas oxygen inhalation， cardiacstrengtheningand diuresis.The treatment group was treated with Danshen Injectiononthebasis of the control group.Both groups received continuous treatment for7days.The changes of coagulation function，hemorheological indicators and cardiac function measurement valuesbefore and after treatment inthe two groups were observed，and the therapeutic efect was evaluated.Result：After treatment，the plasma PTand APTTin the treatment group were longerthan those before treatmentandinthecontrol group，whiletheD-D，FIB，highblood viscosity（HBV），lowblood viscosity （LBV），and plasma viscosity （PV） were allower than those before treatment and in thecontrol group，the differenceswereall statistically significant （ P lt;0.05）.After treatment， theleft ventricular ejection fraction （LVEF） and Pa0₂ in both groups were higher than those before treatment， while the pulmonary artery pressure （PAP） and brain natriuretic peptide （BNP）were lower than those before treatment; moreover，the LVEF and Pa0₂ in the treatment group were higherthan those in the control group，and thePAP and BNP werelower than those in the control group （ P lt;0.05）.

Conclusion： Danshen Injection can efectively improve coagulation function，promote blood circulation，enhance cardiorespiratory function，and improve therapeutic efects in patients with decompensated CPHD.

慢性肺源性心脏病（chronicpulmonaryheartdisease，CPHD）多发于中老年人，主要是由于患者肺功能异常如肺循环阻力过高、肺动脉高压引起的心脏病[]。CPHD失代偿期机体缺氧及肺部血管阻力增多，通常出现咳痰、双下肢水肿等症状，且易形成血栓[2，严重者可出现肺栓塞、心肺功能衰竭等疾病，故早期的预防及治疗尤为重要。丹参注射液是一种具有活血化瘀功效的中成药，安全性良好，其用于冠心病、急性心肌梗死等疾病的治疗已有报道[3，但其治疗CPHD失代偿期的经验及具体机制仍有待明确，本研究旨在基于血栓前状态标志物、心功能指标进一步观察其对CPHD失代偿期患者的辅助治疗价值，以期更好控制病情，为临床更好应用丹参注射液及中西医结合治疗提供理论依据。

1资料与方法

1.1一般资料

选择2023年5月一2024年7月就诊于江西省胸科医院的80例慢性阻塞性肺疾病合并CPHD失代偿期患者。纳入标准：（1）均明确诊断为CPHD失代偿期[4；（2）服从性较好，认知功能正常。排除标准：（1）近期（6个月以内）接受肝素等抗凝药物，严重肝病，风湿免疫病，伴多器官功能衰竭；（2）伴恶性肿瘤及凝血功能障碍；（3）妊娠期或认知功能障碍，不能服从治疗方案；（4）对丹参注射液过敏。按随机数字表法分为对照组及治疗组，各40例。本研究方案经江西省胸科医院医学伦理委员批准，且患者均签署了知情同意书。

1.2方法

对照组给予常规治疗，包括鼻导管低流量吸氧2L/min ，纠正二氧化碳潴留，并根据患者呼吸情况及炎症反应给予祛痰剂、黏液……